2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant

C Valenza,E Nicolo,M Mongillo,D Trapani,F Gigli,L Boldrini,L Boscolo Bielo,G Castellano,L Guidi,J Katrini,G Pellizzari,J Villa,I.T Lorenzetti,S Derio,M.T La Presa,G Parma,G Curigliano,N Colombo

doi:10.1016/j.annonc.2023.09.823

2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant

C Valenza, E Nicolo + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.823

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Oct 1, 2023

Affiliation: European Institute of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico

#Advanced High Grade Ovarian Carcinoma #Myelodysplastic Syndrome/acute Myeloid Leukemia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant

Full Text